Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences

a technology of bioactive agents and transport sequences, applied in the direction of drug compositions, dispersed delivery, immunological disorders, etc., can solve the problems of inability to work well, inconvenient delivery, and inability to meet any kind of match,

Inactive Publication Date: 2015-09-24
THORNHILL THERAPEUTICS INC
View PDF1 Cites 17 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention is about a protein called Cholix that can efficiently move across polarized cells in the airways and intestine. This discovery suggests that certain parts of the Cholix protein can be used to transport proteins and nanoparticles across membranes, which is useful for developing new pharmaceutical applications.

Problems solved by technology

Unfortunately, however, the efficient transport across this simple, single layer of cells remains a substantial barrier due to the intracellular trafficking to destructive lysosome compartments after endosomal uptake of polypeptides at the luminal surface; Woodley, J. F., Crit Rev Ther Drug Carrier Syst, 11(2-3):p.
While transient opening and closing of TJ structures can facilitate transport of peptides across intestinal epithelia, this approach has key limitations: e.g., it does not work well for molecules above ˜5 kDa; it has the potential for non-selective entry of materials into the body from the intestinal lumen; and it represents a route that involves only a small fraction of the surface area of the intestinal epithelium.
Searching the genome of V. cholera for PE-like nucleotide sequences fails to result in a match of any kind.
Nevertheless, Cholix and PE appear to have distinct cell receptor interactions, demonstrating clear differences that are sufficient to suggest very different and unanticipated applications for both oral biologics and the intracellular delivery of bioactive agents.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences
  • Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0056]A plasmid construct was prepared encoding mature Vibrio cholera Cholix and used to express the mature Cholix protein in an E. coli expression system as previously described; see, e.g., Jorgensen, R. et al., J Biol Chem, 283(16):10671-10678 (2008). A non-toxic mutant form of the Cholix gene (hereinafter referred to as “ntCholix”) was also prepared by genetic deletion of a glutamic acid at amino acid position 581 (ΔE581) which is analogous to a deletion (ΔE553) in the PE protein that renders it non-toxic without significantly altering its conformation; Killeen, K. P. and Collier, R. J., Biochim Biophys Acta, 1138:162-166 (1992). Protein expression was achieved using E. coli DH5α cells (Invitrogen, Carlsbad, Calif.) following transformation by heat-shock (1 min at 42° C.) with the appropriate plasmid. Transformed cells, selected on antibiotic-containing media, were isolated and grown in Luria-Bertani broth (Difco). Protein expression was induced by addition of 1 mM isopropyl-D-th...

example 2

[0058]Trans-epithelial transport of ntCholix-Alexa488 was assessed using Caco-2 monolayers in vitro. First, Caco-2 cells (passage number 25-35) were grown to confluent monolayers as previously described; Rubas, W. et al.,Pharm Res, 10:113-118 (1993). Briefly, cells were maintained at 37° C. in DMEM / high growth media enriched with 2 mM L-glutamine, 10% fetal bovine serum, and 100 Units of penicillin / streptomycin in an atmosphere of 5% CO2 and 90% humidity. Cells were passaged every week at a split ratio of 1:3 in 75 cm2 flasks and seeded onto prewetted and collagen-coated permeable (0.4 μm pore size) polycarbonate (Transwell™) filter supports from Corning Costar (Cambridge, Mass.) at a density of 63,000 cells / cm2. Growth media was replaced every other day. Confluent monolayers, determined by the acquisition of significant trans-epithelial resistance (TEER) determine using an volt-ohm-meter (World Precision Instruments, Sarasota, Fla.), were used 20-26 days post seeding.

[0059]Two addi...

example 3

[0062]Also prepared and expressed in E. coli. was a variant of Cholix truncated at amino acid A386 (Cholix386) as well as a genetic ligation of green fluorescent protein (GFP) at the C-terminus of Cholix386 (Cholix386GFP). Protein expression was achieved using E. coli DH5α cells (Invitrogen, Carlsbad, Calif.) following transformation by heat-shock (1 min at 42° C.) with the appropriate plasmid. Transformed cells, selected on antibiotic-containing media, were isolated and grown in Luria-Bertani broth (Difco). Protein expression was induced by addition of 1 mM isopropyl-D-thiogalactopyranoside (IPTG). Two hours following IPTG induction, cells were harvested by centrifugation at 5,000×g for 10 min at 4° C. Inclusion bodies were isolated following cell lysis and proteins were solubilized in 6 M guanidine HCl and 2 mM EDTA (pH 8.0) plus 65 mM dithiothreitol. Following refolding and purification, proteins were stored at ˜5 ml / ml in PBS (pH 7.4) lacking Ca2+ and Mg2+ at −80° C. Cholix386GF...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The field of the present invention relates, in part, to a strategy for novel pharmaceutical applications. More specifically, the present invention relates to a non-toxic mutant form of the Vibrio cholera Cholix gene (ntCholix), a variant of Cholix truncated at amino acid A386 (Cholix386) and the use of other various Cholix-derived polypeptide sequences to enhance intestinal delivery of biologically-active therapeutics. Importantly, the systems and methods described herein provide for the following: the ability to deliver macromolecule doses without injections; the ability to deliver cargo, such as (but not limited to) siRNA or antisense molecules into intracellular compartments where their activity is required; and the delivery of nanoparticles and dendrimer-based carriers across biological membranes, which otherwise would have been impeded due to the barrier properties of most such membranes.

Description

RELATED PATENT APPLICATIONS[0001]This application is a Continuation of U.S. Ser. No. 13 / 822,435, filed Mar. 12, 2013, which claims priority to and benefit of U.S. Provisional Application No. 61 / 403,394, filed on Sep. 15, 2010, each of which is incorporated in its entirety by reference herein.TECHNICAL FIELD[0002]The field of the present invention relates, in part, to a strategy for novel pharmaceutical applications. More specifically, the present invention relates to a non-toxic mutant form of the Vibrio cholera Cholix gene (ntCholix), a variant of Cholix truncated at amino acid A386 (Cholix386) and the use of other various Cholix-derived polypeptide sequences to enhance intestinal delivery of biologically-active therapeutics. Importantly, the systems and methods described herein provide for the following: the ability to deliver macromolecule doses without injections; the ability to deliver cargo, such as (but not limited to) siRNA or antisense molecules into intracellular compartme...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K47/48A61K31/713A61K31/7088
CPCA61K47/48261A61K31/713A61K31/7088A61K47/48338C07K14/28A61K38/212A61K38/27A61K38/28A61K31/7105A61K31/711C07K19/00C07K2319/50A61K47/6415C12Y204/02A61K38/1793A61K38/20A61K38/2066A61K38/26A61K38/45C12N9/1077C12Y204/02036A61K9/4841A61K9/2004A61K9/10A61K9/0095A61K9/0056A61K9/006A61K9/14A61P1/04A61P11/00A61P25/02A61P31/00A61P37/02A61P37/04A61P37/06A61P43/00A61P7/02A61P9/06Y02A50/30A61K47/50A61K9/16A61K38/03A61K47/65A61K9/5184C07K16/241C07K2317/76C07K2319/55A61K9/0053A61K9/20A61K9/48A61K47/64
Inventor MRSNY, RANDALLMAHMOOD, TAHIR
Owner THORNHILL THERAPEUTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap